Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1392&sort=funder
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=funder", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=funder", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1393&sort=funder", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1391&sort=funder" }, "data": [ { "type": "Grant", "id": "11847", "attributes": { "award_id": "1R03AI166727-01A1", "title": "The impact of immune escape on the epidemiology and evolutionary dynamics of the COVID-19 pandemic in Yucatan, Mexico", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 6588, "first_name": "MICHAEL JOHN", "last_name": "Cooper", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-07-11", "end_date": "2025-06-30", "award_amount": 51452, "principal_investigator": { "id": 27737, "first_name": "Guadalupe", "last_name": "Ayora-Talavera", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2052, "ror": "", "name": "AUTONOMOUS UNIVERSITY OF YUCATAN", "address": "", "city": "", "state": "", "zip": "", "country": "MEXICO", "approved": true }, "abstract": "PROJECT SUMMARY: More than two years after the beginning of the COVID-19 pandemic caused by SARS-CoV-2, more than 600 million cases and 6.5 million deaths have been reported worldwide. Genomic and epidemiological analyses of SARS-CoV-2 have provided key understanding of the emergence and evolutionary processes that drive viral mutations and promote antigenic escape and enhanced virus transmission. Preliminary studies reported increased transmissibility for SARS-CoV-2 lineages with the D614G mutation 1, as well as the variants of concern (VOC) Alpha/B.1.1.7, Beta/B.1.351, Gamma/P.1 and Delta/B.1.617.2. The emergence and unprecedented speed of transmission of the VOC Omicron/B.1.1.529 resulted in a significant number of cases worldwide and breakthrough infections in a high proportion of vaccinated individuals. Therefore, there is a continued need to monitor the genomic characteristics of circulating viruses for early identification of new variants with altered immune, transmission or pathogenicity properties, particularly in settings with high infection rates. Mexico ranks third in Latin America in terms of COVID-19 burden with more than 7 million cases as of November 3, 2022, and third worldwide in total number of reported COVID-19 related deaths, with fatalities above 330,000. The COVID-19 pandemic has underlined the gaps in the current surveillance system in Mexico. The genomic epidemiology of SARS-CoV-2 in Mexico is underrepresented and undercharacterized due to limited spatial coverage of viral genomes. Genetic differences between the circulating SARS-CoV-2 viruses in Mexico, the Americas and globally are unclear. Mexico is a vast and diverse country with differences in demography, climate, and significant population mobility, both domestically and internationally, recording 32.4 million US tourists in 2019 5. Our previous work on influenza virus in Yucatan showed strong evidence that seasonality and the occurrence of genetic variants vary greatly across the country, which encompasses temperate and tropical regions 6,7. Thus examining the genomic epidemiology of SARS-CoV-2 in Mexico, particularly in highly touristic states such as Yucatan, will shed light on the viral diversity and transmission dynamics in the country, and clarify evolutionary changes as the disease becomes endemic. Because of tight connections between Mexico and the US, these analyses will also contribute to informing public health interventions in both nations. This project leverages existing and newly generated data on SARS-CoV-2 in Yucatan and consequently in Mexico, enabling: 1) epidemiological and mathematical modeling to evaluate changes in viral dissemination and diversity in the context of vaccination campaigns and changes in population mobility, and estimate the fitness advantage of new variants on a population level, and 2) characterize circulating variants by generating genomic sequences and reconstructing the evolutionary history and migrations that led to the emergence or introduction of locally circulating lineages. Genomic and phylodynamic analysis, in conjunction with mathematical modeling, have provided powerful tools to understand and predict the fate of new SARS-CoV-2 variants elsewhere 8. An integrated capacity for outbreak analytics combining genomics, phylodynamics and mathematical modeling is lacking in Yucatan, Mexico. This work will build local capacity to address these questions and have a significant public health impact by providing accurate information about COVID-19 transmission dynamics.", "keywords": [ "2019-nCoV", "Address", "Age", "Americas", "Archives", "Authorization documentation", "Automobile Driving", "COVID-19", "COVID-19 mortality", "COVID-19 pandemic", "Cessation of life", "Characteristics", "Circulation", "Climate", "Clinical", "Country", "Data", "Databases", "Demography", "Disease", "Disease Outbreaks", "Early identification", "Effectiveness", "Epidemiological trend", "Epidemiology", "Event", "Genetic", "Genomics", "Geography", "Goals", "Health", "Immune", "International", "Intervention", "Laboratories", "Latin America", "Measures", "Mexico", "Monitor", "Mutation", "Pathogenicity", "Patients", "Population", "Population Dynamics", "Process", "Property", "Prospective Studies", "Public Health", "Recording of previous events", "Reporting", "Reproduction", "Reverse Transcription", "Route", "SARS-CoV-2 B.1.1.7", "SARS-CoV-2 B.1.351", "SARS-CoV-2 B.1.617.2", "SARS-CoV-2 transmission", "SARS-CoV-2 variant", "Sampling", "Seasons", "Specimen", "Speed", "System", "Time", "Travel", "Universities", "Vaccination", "Vaccinee", "Vaccines", "Variant", "Viral", "Viral Genome", "Virus", "Work", "authority", "breakthrough infection", "comorbidity", "data integration", "emerging pathogen", "epidemiologic data", "epidemiological model", "fitness", "genetic variant", "genomic data", "genomic epidemiology", "infection rate", "influenzavirus", "interest", "mathematical model", "migration", "public health intervention", "repository", "response", "sex", "tool", "transmission process", "variants of concern", "viral transmission", "virology" ], "approved": true } }, { "type": "Grant", "id": "11852", "attributes": { "award_id": "1R21AI174041-01", "title": "Oral Antivirals against COVID-19 and Clinical Outcomes in High Risk Populations", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 6243, "first_name": "BROOKE ALLISON", "last_name": "Bozick", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-07-12", "end_date": "2025-06-30", "award_amount": 157813, "principal_investigator": { "id": 27746, "first_name": "ADEEL A", "last_name": "BUTT", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2054, "ror": "", "name": "VETERANS HEALTH FOUNDATION", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "COVID-19 has led to over 350 million reported cases and over 5.6 million resulting deaths globally, and nearly 72 million cases and >900,000 deaths in the US. Highly effective vaccines are now available and are the first line of defense. However, immunity wanes off over time and breakthrough infections in fully vaccinated persons have been reported, particularly with the newer variants. In December 2021, two novel oral antiviral agents, Nirmatrelvir/ritonavir (NMV/r) and Molnupiravir (MPV), were granted Emergency Use Authorization (EUA) by the FDA for treatment of early symptomatic patients with mild to moderate COVID-19 at high risk of progression to severe disease. These authorizations were granted based on limited published data, and critical questions about their comparative effectiveness, effectiveness in the real-world settings, and effectiveness in specific high-risk sub-populations remain to be answered. There is an urgent need to understand the real-world effectiveness of these drugs, especially in the high-risk and vulnerable populations, as well as longer term clinical outcomes in treated patients. Such knowledge is essential for the patients, providers, payors, and policymakers, to ensure that they are used only in the appropriate populations and situations based on strong clinical evidence. To address these critical gaps in knowledge, we propose the following hypotheses: Hypothesis 1: Treatment with NMV/r or MPV will be associated with a significant reduction in COVID-19 related hospitalization and 30-day all-cause mortality in older persons, those with a high comorbidity burden, and in socially vulnerable persons. Hypothesis 2: We hypothesize that NMV/r and MPV treatment will be associated with a significant reduction in subsequent hospital admissions, emergency department visits, and outpatient clinic visits over a 1-year period after recovery. Treatment will also be associated with a lower incidence of acute myocardial infarction, stroke, decline in renal function, and diabetes, compared with propensity-score matched untreated persons. We will use the Department of Veterans Affairs’ COVID-19 Shared Data Resource (VA ORDCOVID) which contains extensive demographic, clinical, pharmacologic, laboratory, vital signs and clinical outcomes information derived from multiple validated sources. We will compare those treated with NMV/r or MPV with propensity-score matched untreated controls, matched on demographics, clinical variables, severity of presenting illness, geographic location, time of treatment, vaccination status, time from completion of a full course of vaccination, and booster dose administration. The PI, Dr. Butt has extensive experience in creating and analysing large national databases and has published 45 papers on COVID-19 in journals including the New England Journal of Medicine, Annals of Internal Medicine, JAMA Internal Medicine, Journal of Clinical Investigation, Nature Medicine, and others. He already has IRB approval to study the epidemiology, natural history, and clinical outcomes of SARS-CoV-2 infection in the VA population.", "keywords": [ "Acute myocardial infarction", "Address", "Affect", "Ambulatory Care Facilities", "Antiviral Agents", "Authorization documentation", "COVID-19", "Cardiovascular system", "Caring", "Case Study", "Cessation of life", "Characteristics", "Clinic Visits", "Clinical", "Collaborations", "Communicable Diseases", "Data", "Databases", "Diabetes Mellitus", "Diagnosis", "Disease", "Disparity", "Early treatment", "Effectiveness", "Elderly", "Emergency Situation", "Emergency department visit", "Endocrine system", "Event", "FDA Emergency Use Authorization", "Geographic Locations", "Grant", "Hepatic", "Homelessness", "Hospitalization", "Immunity", "Incidence", "Institutional Review Boards", "Internal Medicine", "International", "Journals", "Kidney", "Knowledge", "Laboratories", "Medical", "Medicine", "Mental disorders", "Metabolic", "Natural History", "Nature", "New Agents", "New England", "Oral", "Outcome", "Paper", "Patients", "Peer Review", "Persons", "Pharmaceutical Preparations", "Policy Maker", "Population", "Poverty", "Provider", "Publications", "Publishing", "Recovery", "Renal function", "Reporting", "Risk", "Ritonavir", "Role", "SARS-CoV-2 infection", "Severities", "Source", "Stroke", "Therapeutic Agents", "Time", "United States Department of Veterans Affairs", "United States Food and Drug Administration", "Update", "Vaccination", "Vaccinee", "Vaccines", "Variant", "Vulnerable Populations", "authority", "booster vaccine", "breakthrough infection", "clinical investigation", "clinical practice", "comorbidity", "comparative effectiveness", "data sharing networks", "data warehouse", "demographics", "effectiveness evaluation", "effectiveness study", "epidemiology study", "ethnic minority", "evidence base", "experience", "gastrointestinal", "health care service utilization", "high risk", "high risk population", "molnupiravir", "mortality", "nirmatrelvir", "novel", "pharmacologic", "physically handicapped", "prevent", "public health emergency", "racial minority", "residence", "respiratory", "social vulnerability" ], "approved": true } }, { "type": "Grant", "id": "11853", "attributes": { "award_id": "1K23AI177952-01", "title": "SARS-CoV-2 in Pregnancy: Comparison of Natural Infection and Hybrid Immunity in Mother-Infant Pairs", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 6243, "first_name": "BROOKE ALLISON", "last_name": "Bozick", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-07-05", "end_date": "2028-06-30", "award_amount": 203580, "principal_investigator": { "id": 27747, "first_name": "Mary Catherine", "last_name": "Cambou", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 818, "ror": "", "name": "UNIVERSITY OF CALIFORNIA LOS ANGELES", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "While the clinical spectrum of SARS-CoV-2 infection in pregnancy ranges from asymptomatic to critical disease, pregnancy itself augments the risk of severe and critical COVID-19. The leading obstetrical societies in the U.S. recommend COVID-19 messenger RNA (mRNA) vaccination in pregnancy to prevent severe disease. Furthermore, passive immunity to the neonate via transplacental transfer of immunoglobulin G (IgG) is critically important during the first six months of life, particularly as the COVID-19 vaccines are approved only for children >six months of age. Hybrid immunity, defined as vaccine-induced immunity before or after natural infection with SARS-CoV-2, produces a more robust response in non-pregnant populations than either type in isolation. The long-term inflammatory and immunologic responses to SARS-CoV-2 hybrid immunity in pregnancy, a state marked by tightly regulated T cell control and immune modulation, compared to natural infection are unknown. As SARS-CoV-2 becomes endemic, this proposal will address a gap in the literature that has focused primarily on natural SARS-CoV-2 infection in pregnancy compared to vaccine-induced immunity. Leveraging the existing COVID-19 Outcomes in Mother-Infant Pairs (COMP) study, a longitudinal cohort that follows 225 mother-infant dyads diagnosed with SARS-CoV-2 infection in pregnancy, the proposal seeks to better understand the long- term consequences of SARS-CoV-2 hybrid immunity in pregnancy. We hypothesize that SARS-CoV-2 hybrid immunity compared to natural infection in pregnancy confers protection against postpartum complications, leads to less maternal systemic inflammation, and results in more robust immune responses in mother-infant pairs. The study aims are: 1) to estimate the prevalence and risk factors of peripartum and delayed postpartum complications of COVID-19 in pregnancy between those with SARS-CoV-2 hybrid immunity, and those with natural infection; 2) to compare the systemic inflammatory landscapes, as measured by cytokine profiles, of pregnant women with SARS-CoV-2 hybrid immunity and natural infection at delivery and one year postpartum; and 3) to evaluate cellular and humoral immune responses to the ancestral and Omicron (BA.5) strains following COVID-19 in pregnancy at delivery and six months postpartum in mother-infant dyads with SARS-CoV-2 hybrid immunity compared to natural infection. The K23 will support Dr. Cambou to develop advanced skills in 1) applied immunology, 2) perinatal infections, and 3) cytokine analysis, in order to become an effective translational physician-scientist. Dr. Karin Nielsen, a world-renowned pediatric infectious diseases (ID) expert in perinatal infections, will serve as the primary mentor. Co-mentors Drs. Otto O. Yang and Grace Aldrovandi, experts in viral immunology, have over 20 years of continuous NIH funding and proven track records of successful mentorship. Co-mentor Dr. Debika Bhattacharya will offer guidance as an adult ID clinical researcher in perinatal viral infections. The K23 will allow Dr. Cambou to carve out a unique niche of multidisciplinary research blending immunology with viral infections in pregnancy, in order to launch her career as an independent investigator.", "keywords": [ "2019-nCoV", "Address", "Adult", "Age Months", "Biological Assay", "Birth", "CD8-Positive T-Lymphocytes", "COVID-19", "COVID-19 complications", "COVID-19 diagnosis", "COVID-19 severity", "COVID-19 treatment", "COVID-19 vaccine", "Childhood", "Clinical", "Communicable Diseases", "Data", "Diagnosis", "Discipline of obstetrics", "Disease", "Enzyme-Linked Immunosorbent Assay", "Fetal health", "Foundations", "Funding", "Future", "Hybrids", "Immune", "Immune response", "Immunity", "Immunoglobulin G", "Immunology", "Infant", "Infection", "Inflammatory", "Inflammatory Response", "Interdisciplinary Study", "Interferon Type II", "Knowledge", "Life", "Literature", "Longitudinal cohort", "Maternal Health", "Measures", "Mentors", "Mentorship", "Messenger RNA", "Mothers", "Neonatal", "Neutralization Tests", "Nucleocapsid", "Only Child", "Outcome", "Participant", "Passive Immunity", "Perinatal", "Perinatal Infection", "Peripheral Blood Mononuclear Cell", "Phase", "Population", "Postpartum Period", "Pregnancy", "Pregnant Women", "Prevalence", "Proteins", "RNA vaccination", "Recommendation", "Records", "Research Personnel", "Risk", "Risk Factors", "Role", "SARS-CoV-2 antibody", "SARS-CoV-2 infection", "SARS-CoV-2 spike protein", "Scientist", "Serology", "Seroprevalences", "Site", "Societies", "T cell response", "T-Lymphocyte", "Testing", "Therapeutic", "Time", "Translating", "United States National Institutes of Health", "Vaccination", "Vaccines", "Viral", "Virus", "Virus Diseases", "biomarker development", "biomarker identification", "career", "cytokine", "emerging pathogen", "env Gene Products", "immunoregulation", "improved", "insight", "maternal morbidity", "maternal outcome", "maternal risk", "neonatal health", "neonate", "neutralizing antibody", "pandemic disease", "pathogenic virus", "placental transfer", "post SARS-CoV-2 infection", "postpartum complications", "prevent", "receptor binding", "response", "risk stratification", "skills", "sociodemographics", "stem", "systemic inflammatory response", "therapeutic development", "translational physician", "treatment guidelines", "vaccine development", "vaccine strategy", "vaccine-induced immunity" ], "approved": true } }, { "type": "Grant", "id": "11858", "attributes": { "award_id": "1R01DC021301-01", "title": "Characterizing the Effects of Chronic Substance Misuse on Auditory and Vestibular Function", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Deafness and Other Communication Disorders (NIDCD)" ], "program_reference_codes": [], "program_officials": [ { "id": 23321, "first_name": "Kelly Anne", "last_name": "King", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-07-03", "end_date": "2028-06-30", "award_amount": 742593, "principal_investigator": { "id": 27748, "first_name": "Amanda", "last_name": "Chiao", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1987, "ror": "", "name": "TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER AT EL PASO", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "Accumulating reports indicate that substance use disorders (SUDs) and overdoses result in hearing loss (HL) and vestibular loss (VL). This is problematic because hearing and balance are important for communication, employment, mental health, physical independence, and overall quality of life. HL and VL would have a greater negative impact on people with SUDs, as this population already struggles with a higher incidence of mental health issues, unemployment, and poorer quality of life. People of minority status with HL/VL are further marginalized because of socioeconomic and/or cultural barriers to audiological healthcare. Unfortunately, the literature on substance-misuse-related HL is sporadic and primarily consists of case reports describing various degrees of either temporary or permanent HL from illicit drugs or prescribed opioid misuse. Even less is known about the effects of SUDs on the vestibular system. A few studies indicate alcohol misuse impairs balance, and opioids and alcohol disrupt peripheral and central vestibular function. The existing studies suggest differential effects on the inner ear based on substance type and use patterns. There is a critical lack of rigorous research using objective measures to identify the peripheral and central effects of SUDs on hearing and vestibular function. Likewise, the influence of health comorbidity, demographics, socioeconomic position, and substance-use patterns on HL/VL in the SUD population has not been investigated. Our project goals are to improve our knowledge of the impact of SUDs on hearing and vestibular function and to identify who is most at risk for HL/VL. To accomplish these goals, we will be the first to investigate peripheral and central hearing (Aim 1) and vestibular (Aim 2) function in a large cohort of diverse people who have SUDs, recruited across three regionally unique study sites. Data will be compared to an age-sex-race or ethnicity-matched control group without SUDs. Last, we will determine the predictive health, demographic, socioeconomic, and substance-use factors that increase the risk of developing HL/VL secondary to substance misuse (Aim 3). We hypothesize that chronic substance misuse will affect the auditory and/or vestibular systems like mechanisms underlying oto- vestibulotoxic medications. Based on the literature, we hypothesize that more health comorbidities, older age, being of non-Hispanic White background, lower socioeconomic position, and riskier substance-use patterns will predict the severity of HL or VL. Biological sex differences are unclear in the existing HL/VL literature; however, our results will help elucidate sex differences in HL/VL and SUDs. SUDs and overdoses have significantly increased since the coronavirus pandemic and disproportionately so among minority populations. Thus, this work is timely and important because early HL/VL intervention is key to minimizing health and social burdens, but care is impeded in SUD and minority populations. Our findings will enhance awareness among professionals who serve people with SUDs so they can make appropriate diagnoses and recommendations. The results will inform our future work to develop accessible, equitable interventions for people with SUDs and health disparities.", "keywords": [ "Accidents", "Adult", "Affect", "Afferent Pathways", "Age", "Alcohols", "Anxiety", "Audiology", "Auditory", "Auditory Brainstem Responses", "Automobile Driving", "Awareness", "Biological", "Biometry", "Caring", "Case Study", "Chronic", "Cochlea", "Cochlear Hearing Loss", "Communication", "Communication Barriers", "Complication", "Control Groups", "Data", "Development", "Diagnosis", "Diagnostic", "Early identification", "Employment", "Epidemiology", "Equilibrium", "Equity", "Ethnic Origin", "Frequencies", "Functional disorder", "Future", "Goals", "Hair Cells", "Head", "Health", "Healthcare", "Hearing", "Hearing Tests", "Illicit Drugs", "Incidence", "Intervention", "Ischemia", "Knowledge", "Labyrinth", "Literature", "Measures", "Medicine", "Mental Health", "Minority", "Minority Groups", "Modeling", "Noise", "Not Hispanic or Latino", "Opioid", "Otolaryngology", "Outcome", "Overdose", "Participant", "Patients", "Pattern", "Peripheral", "Personal Satisfaction", "Persons", "Pharmaceutical Preparations", "Physiological", "Physiology", "Population", "Positioning Attribute", "Prevalence", "Probability", "Quality of life", "Questionnaires", "Race", "Recommendation", "Recovery", "Rehabilitation therapy", "Reporting", "Research", "Research Design", "Residual state", "Risk", "Risk Factors", "Secondary to", "Severities", "Sex Differences", "Site", "Societies", "Socioeconomic Status", "Speech Perception", "Substance Use Disorder", "System", "Testing", "Time", "Trauma", "Unemployment", "Vascularization", "Vestibular Hair Cells", "Vestibular loss", "Visual Acuity", "Work", "addiction", "alcohol misuse", "behavior measurement", "biological sex", "childhood hearing loss", "cohort", "comorbidity", "demographics", "equilibration disorder", "fall risk", "health disparity", "hearing impairment", "hearing loss risk", "hearing range", "human old age (65+)", "improved", "low socioeconomic status", "marginalization", "minority communities", "minority health disparity", "novel", "oculomotor", "opioid misuse", "otoacoustic emission", "ototoxicity", "pandemic coronavirus", "permanent hearing loss", "physical conditioning", "prescription opioid", "recruit", "risk prediction", "sex", "social", "social factors", "socioeconomics", "speech in noise", "substance misuse", "substance use", "vestibular pathway" ], "approved": true } }, { "type": "Grant", "id": "11861", "attributes": { "award_id": "1UG3MH133258-01", "title": "Identifying socioecological profiles that impact changes in care outcomes among Black Sexual minority men living with HIV", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 21190, "first_name": "Michael J", "last_name": "Stirratt", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-07-15", "end_date": "2025-05-31", "award_amount": 898737, "principal_investigator": { "id": 27754, "first_name": "Derek Tramel", "last_name": "Dangerfield II", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 27755, "first_name": "DEMARC A", "last_name": "HICKSON", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 174, "ror": "https://ror.org/00y4zzh67", "name": "George Washington University", "address": "", "city": "", "state": "DC", "zip": "", "country": "United States", "approved": true }, "abstract": "The U.S. will not meet the targets of the Ending the HIV Epidemic Plan (EHE) without an intentional focus on improving outcomes among Black sexual minority men living with HIV (BSMM LWH). Only 55% of BSMM LWH maintain 100% daily treatment adherence and only 62% are virally suppressed. Research proves that multilevel factors such as racism, stigma, depression, victimization, and economic instability are important unaddressed determinants of HIV care outcomes. Updates to health care delivery models due to COVID-19 (i.e. telehealth) provided novel ways to improve HIV care engagement, retention, and adherence. However, BSMM still experience worse outcomes than others even when accounting for differences in access to resources. The literature collectively suggests that multilevel factors could create distinct socioecological patterns that impact HIV care outcomes for BSMM LWH, especially across age groups. BSMM LWH have not adequately engaged or retained in care activities because previous approaches do not account for their current or combined socioecological experiences. Previous studies are outdated, cross-sectional, utilize culturally inappropriate measures, and have small samples of Black participants. Sustainable approaches to engage this population remain elusive, especially for young BSMM LWH. There is no digital, limited interaction cohort study centered on BSMM LWH despite focus given to other priority populations such as transwomen, drug users, and adolescents. The goal of this Limited Interaction Targeted Epidemiology proposal is to conduct a prospective cohort study to identify the HIV care riskscape for BSMM LWH and examine how multilevel factors impact changes in retention in HIV care, treatment adherence, and viral suppression. Phase 1 will identify effective recruitment strategies (Aim 1) and validate commonly accepted scales among BSMM LWH to aid in survey design (Aim 2). Then we will explore the feasibility and acceptability of enrolling a large digital cohort of Mid-Atlantic BSMM LWH (Aim 3). Phase 2 will collect and analyze prospective cohort data collected at baseline, 3-months, 6-months to quantify the cross sectional and longitudinal relationships between multilevel factors and HIV care outcomes among 1,500 BSMM LWH (Aim 4). This study will be the largest prospective cohort focused on BSMM LWH ever conducted and targets high-priority EHE locales. This study aligns with NIH priorities to map longitudinal trajectories of the HIV care continuum, identify predictors of changes in viral suppression, and support large studies led by Black investigators. This work also builds upon the existing collaboration, resources, and support of the Mid Atlantic CFAR Consortium and is the next step needed in our work to design equitable approaches to improve HIV care outcomes for BSMM LWH.", "keywords": [ "Accounting", "Adherence", "Adolescent", "Baltimore", "Black race", "COVID-19", "Caring", "Chi-Square Tests", "Cities", "Cohort Studies", "Collaborations", "Continuity of Patient Care", "Data", "Drug usage", "Drug user", "Economics", "Enrollment", "Epidemiology", "Equity", "Generations", "Goals", "HIV", "High Prevalence", "Incidence", "Knowledge", "Life Cycle Stages", "Literature", "Locales", "Longitudinal Studies", "Maps", "Measures", "Medical", "Mental Depression", "Methods", "Modeling", "Outcome", "Participant", "Pattern", "Phase", "Philadelphia", "Population", "Prospective Studies", "Prospective cohort", "Prospective cohort study", "Psychometrics", "Research", "Research Personnel", "Resources", "Risk", "Sampling", "Service delivery model", "Sexuality", "Surveys", "Target Populations", "United States National Institutes of Health", "Update", "Victimization", "Viral", "Washington", "Work", "acceptability and feasibility", "age group", "age related", "care outcomes", "cohort", "design", "differences in access", "digital", "effectiveness testing", "epidemic preparedness", "experience", "health care service organization", "improved", "improved outcome", "longitudinal analysis", "marginalized population", "men", "novel", "prospective", "racism", "recruit", "sexual minority men", "social stigma", "telehealth", "theories", "transgender women", "treatment adherence", "trend" ], "approved": true } }, { "type": "Grant", "id": "11863", "attributes": { "award_id": "1R01MD018730-01", "title": "Dime la VerDAD (Verify, Debunk, and Disseminate)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Minority Health and Health Disparities (NIMHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 6103, "first_name": "Nancy Lynne", "last_name": "Jones", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-07-10", "end_date": "2027-12-31", "award_amount": 702357, "principal_investigator": { "id": 27759, "first_name": "MARINA", "last_name": "DEL RIOS", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 220, "ror": "https://ror.org/036jqmy94", "name": "University of Iowa", "address": "", "city": "", "state": "IA", "zip": "", "country": "United States", "approved": true }, "abstract": "Social media has accelerated the spread of vaccine misinformation leading to decreased immunization rates and increased preventable deaths in the US and globally. The health impact of misinformation is particularly critical to understand and address when considering the lives of minoritized racial and ethnic groups who are often the target of misinformation campaigns or who may not have easy access to culturally relevant and language-concordant reputable sources. Although access to vaccines remains a significant barrier, vaccine safety confidence is a significant predictor of influenza and COVID vaccination in Hispanic adults. Yet, little is known about how misinformation narratives emerge specifically in relation to Hispanic communities, how they are disseminated, and how they ultimately affect people’s decision to get vaccinated. Social media posts that include personal narratives are more effective at communicating reliable health recommendations, especially those that come from a trusted peer. Therefore, communication strategies that leverage community and interpersonal relationships can prove extremely effective at debunking misinformation about vaccines. Promotores de salud are trusted community members who serve as links between health/social services and a community to improve access to health services and quality of service delivery. Promotores can diffuse and address misinformation in their communities and can be essential to debunk myths, increase trust, and improve health outcomes; they have been at the forefront of addressing disparities in COVID testing and vaccine uptake. Promotores de salud are uniquely positioned as trusted messengers to debunk vaccine misinformation through strategic use of social media and infodemiology principles. Dime La VerDAD (Verify, Debunk, and Disseminate) is an innovative social media capacity-building program based on theoretical frameworks related to health communication that empowers promotores de salud to debunk vaccine misinformation through the use of personal narratives on social media. The proposed work will use a rigorous stepped wedge design to 1) deliver a scalable program of science communicators using an adapted curriculum grounded in infodemiology, 2) evaluate how debunking misinformation is perceived on social media, and 3) discern how use of personal narratives to enhance science communication can lead to changes in opinions and behavior (vaccination rates) about COVID and influenza vaccines among Chicago’s predominantly Hispanic communities.", "keywords": [ "Acceleration", "Address", "Adult", "Affect", "Amplifiers", "Attitude", "Behavior", "COVID-19", "COVID-19 disparity", "COVID-19 pandemic", "Chicago", "Cities", "Communication", "Communities", "Community Health Aides", "Diffuse", "Educational Curriculum", "Effectiveness", "Ethnic Population", "Evaluation", "Face", "Focus Groups", "Health", "Health Professional", "Health Services Accessibility", "Hispanic", "Hispanic Populations", "Household", "Illinois", "Immunization", "Improve Access", "Infection", "Influenza", "Influenza vaccination", "Infodemiology", "Interpersonal Relations", "Interview", "Knowledge", "Language", "Learning", "Link", "Measures", "Medical", "Misinformation", "Modeling", "Occupational Exposure", "Outcome", "Participant", "Perception", "Persons", "Positioning Attribute", "Process", "Recommendation", "Science", "Social Network", "Social Work", "Source", "Standardization", "Subgroup", "Surveys", "Testing", "Training", "Training Programs", "Translating", "Trust", "Vaccinated", "Vaccination", "Vaccines", "Work", "combat", "community engagement", "coronavirus disease", "design", "digital", "effectiveness testing", "empowerment", "experience", "health care availability", "health communication", "health disparity", "hispanic community", "improved", "influenza virus vaccine", "informant", "innovation", "member", "multidisciplinary", "pandemic disease", "peer", "personal narratives", "prevent", "preventable death", "programs", "racial minority population", "recruit", "service delivery", "skills", "social", "social media", "testing uptake", "tool", "uptake", "vaccine acceptance", "vaccine access", "vaccine development", "vaccine hesitancy", "vaccine safety" ], "approved": true } }, { "type": "Grant", "id": "11868", "attributes": { "award_id": "1R01AI177859-01", "title": "Expanding Swabseq sequencing technology to enable readiness for emerging pathogens", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 6588, "first_name": "MICHAEL JOHN", "last_name": "Cooper", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-07-11", "end_date": "2028-06-30", "award_amount": 573160, "principal_investigator": { "id": 27762, "first_name": "Valerie A", "last_name": "Arboleda", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 27764, "first_name": "ELEAZAR", "last_name": "ESKIN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 818, "ror": "", "name": "UNIVERSITY OF CALIFORNIA LOS ANGELES", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "This application aims to develop improved methods for detecting novel pathogens that can be deployed on a large scale and are flexible to multiple pathogens. The method uses the power of next generation sequencing technology to analyse hundreds of thousands of samples simultaneously. In contrast to standard clinical testing, where one person's sample is tested in a single tube, mass testing labels each person's sample with a unique piece of DNA that acts as a molecular barcode, then pools multiple samples together so that they can be jointly tested. DNA sequencing is then used to detect those samples with virus in the pool of hundreds of thousands of individuals, and assign the virus to the samples it came from on the basis of the molecular barcodes. A bench top sequencer can process tens of thousands a day. A larger machine generates enough sequence to run up to hundreds of thousands of tests in one day. Our aim is to make it possible for a moderately well-equipped molecular biology laboratory to be able to process tens of thousands of samples without much investment. We have successfully deployed SwabSeq testing at the high-complexity, CLIA-certified, UCLA SwabSeq COVID19 Testing laboratory. Our work has demonstrated the utility for high-throughput asymptomatic testing and with additional improvements can increase testing capacity by orders of magnitude, making it possible to deploy testing on a population scale. Our sequencing-based approach can be extended to also detect viral variants at the same time and to other viral pathogens. Mass testing will f nd asymptomatic carriers and thus inform public health policies so that containment of infection will be effective.", "keywords": [ "2019-nCoV", "Algorithmic Analysis", "Area", "Bar Codes", "Biological Assay", "CLIA certified", "COVID-19", "COVID-19 detection", "COVID-19 pandemic", "COVID-19 screening", "COVID-19 testing", "Calibration", "Cessation of life", "Clustered Regularly Interspaced Short Palindromic Repeats", "Coccidioidomycosis", "Collection", "Communicable Diseases", "Contact Tracing", "Containment", "Coupled", "DNA", "DNA sequencing", "Detection", "Diagnosis", "Disease", "Disease Outbreaks", "Excision", "Failure", "Genomics", "Goals", "Health", "Health Policy", "Hospitalization", "Hour", "Human", "Human poliovirus", "Individual", "Infection", "International", "Investments", "Label", "Laboratories", "Light", "Link", "Masks", "Mass Screening", "Measures", "Methodology", "Methods", "Molecular", "Molecular Biology", "Monkeypox", "Nested PCR", "Nucleic Acids", "Patients", "Persons", "Poliomyelitis", "Population", "Probability", "Process", "Protocols documentation", "Public Health", "Quarantine", "RNA", "Rapid screening", "Reaction", "Readiness", "Reagent", "Research", "Reverse Transcriptase Polymerase Chain Reaction", "Reverse Transcription", "Running", "Sampling", "Series", "Specimen", "Swab", "Symptoms", "Technology", "Test Result", "Testing", "Time", "Travel", "Tube", "Vaccination", "Variant", "Viral", "Virus", "Vision", "Work", "clinical development", "clinical diagnostics", "combinatorial", "commensal bacteria", "cost", "current pandemic", "desert fever", "design", "detection limit", "detection method", "emerging pathogen", "flexibility", "future pandemic", "high throughput screening", "improved", "indexing", "innovation", "next generation", "next generation sequencing", "novel", "pandemic disease", "pandemic response", "pathogen", "pathogenic bacteria", "pathogenic fungus", "pathogenic virus", "research clinical testing", "saliva sample", "scale up", "surveillance network", "technology development", "transcriptome sequencing", "transmission process", "variant detection", "viral detection" ], "approved": true } }, { "type": "Grant", "id": "11874", "attributes": { "award_id": "3R01HL160703-01A1S1", "title": "The 3E Study: Economic and Educational Contributions to Emerging Adult Cardiometabolic Health", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 26922, "first_name": "Jared P", "last_name": "Reis", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-07-15", "end_date": "2025-12-31", "award_amount": 11834, "principal_investigator": { "id": 26923, "first_name": "Alison", "last_name": "Cohen", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 26924, "first_name": "Lindsay Till", "last_name": "Hoyt", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1974, "ror": "https://ror.org/03qnxaf80", "name": "Fordham University", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "College is a time of changing socioeconomic position (SEP) that is not often clearly captured in health research, despite strong ties between SEP and health. Over one-third of college students report being overweight or obese, and the incidence of cardiovascular disease outcomes among young adults has been an increasing cause of concern. This risk is exacerbated for low-SEP students, and students of color, especially since the COVID-19 pandemic began. The proposed longitudinal research addresses these important scientific gaps by creating and studying a de novo, longitudinal cohort of 4,000 racially, ethnically, and socioeconomically diverse young adult college students recruited as first-year students from two HSIs in California and followed over three years, regardless if they leave or stay in college. To best recruit and retain students, an undergraduate student researcher from the population of interest will provide insight into how best recruit and retain study participants. They will conduct a literature review on how best to recruit and retain students from racially diverse campuses with high proportions of students who are pell grant eligible and the first in their family to go to college and assist in creating and modifying recruitment and retention materials that are culturally appropriate, ethical and effective. The study will incorporate anthropometric, institutional administrative, smartphone, behavioral, and self-reported data. The specific aims are: (1) To determine the contribution of emerging adults’ economic stressors (e.g.,income, wealth, financial stress, basic needs, residential environment, subjective social status) to cardiometabolic health outcomes (e.g., weight-related measures, blood pressure) over time; (2) To determine the contribution of educational protective factors (e.g., use of social supports, academic supports, basic needs supports) to cardiometabolic health outcomes over time; (3) examine weight-related behaviors (i.e., sleep, physical activity, diet, disordered eating, smoking) as mechanisms of associations between economic stress, educational protective factors, and cardiometabolic health. This large, diverse sample will allow us to examine how racialized and gendered identities may modify associations between economic and educational exposures and cardiometabolic outcomes, which will help increase understanding of the complex interplay between different social determinants of health and help inform potential interventions to reduce health disparities.", "keywords": [ "Academic support", "Address", "Behavior", "Behavioral", "Blood Pressure", "COVID-19 pandemic", "California", "Cardiovascular Diseases", "Cellular Phone", "Color", "Complex", "Data Reporting", "Diet", "Disease Outcome", "Eating Disorders", "Economics", "Education", "Eligibility Determination", "Ensure", "Environment", "Ethics", "Ethnic Origin", "Family", "Financial Hardship", "Gender Identity", "Goals", "Grant", "Health", "Incidence", "Income", "Institution", "Intervention", "Longitudinal cohort", "Measures", "Obesity", "Outcome", "Overweight", "Participant", "Patient Self-Report", "Physical activity", "Population", "Race", "Reduce health disparities", "Reporting", "Research", "Research Personnel", "Review Literature", "Risk", "Sampling", "Sleep", "Smoking", "Social status", "Social support", "Socioeconomic Status", "Stress", "Student recruitment", "Students", "Time", "Underrepresented Students", "Weight", "cardiometabolism", "college", "emerging adult", "ethnic diversity", "insight", "interest", "low socioeconomic status", "protective factors", "racial diversity", "racial identity", "recruit", "social health determinants", "socioeconomics", "stressor", "student retention", "success", "undergraduate student", "university student", "young adult" ], "approved": true } }, { "type": "Grant", "id": "11876", "attributes": { "award_id": "1R21AI166898-01A1", "title": "Programming designer DNA nanostructures for blocking enveloped viral infection", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 6115, "first_name": "DIPANWITA", "last_name": "Basu", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-07-14", "end_date": "2025-06-30", "award_amount": 203149, "principal_investigator": { "id": 27771, "first_name": "Weishan", "last_name": "Huang", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 5608, "first_name": "Xing", "last_name": "Wang", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1505, "ror": "", "name": "LOUISIANA STATE UNIV A&M COL BATON ROUGE", "address": "", "city": "", "state": "LA", "zip": "", "country": "United States", "approved": true }, "abstract": "SARS-CoV-2, the etiological pathogen of COVID-19, has resulted in a pandemic. There remains an urgent need for innovative technologies which facilitate the development of affordable antiviral precision medicine. SARS-CoV-2 is an enveloped virus, and the structure of the trimeric spike protein clusters on the virion has been solved. To develop innovative, affordable, and biocompatible antiviral candidates against SARS-CoV-2 infection and transmission, we exploited the structural characteristics of viral surface proteins that can be matched at nanoscale precision by engineered DNA nanostructure platforms. Based on the structure of the SARS-CoV-2 virion and surface spike trimer layout, we have synthesized a designer DNA nanostructure (DDN) that takes the form of a macromolecular ‘net’ whose vertices are a precise mechanical match to the spacing and positioning of the spike protein matrix displayed on the virus outer surface. We hypothesize that the structural properties and the layout patterns of SARS-CoV-2 spike proteins can be exploited to design DDNs with nanoscale precision which are capable of matching and capturing intact SARS-CoV-2 virions with ultrahigh binding avidity and selectivity, thereby blocking SARS-CoV-2 infection. We have screened and found DNA aptamers and nanobodies that are specific for the spike receptor-binding domain (RBD). These spike binders can be incorporated into the ‘knots’ of the DDN net to allow the simultaneous binding of multiple DNA aptamers with multiple spikes on the viral surface in a polyvalent, pattern-matching fashion. The DNA ‘net’-aptamer prototype construct has afforded dramatic increase in SARS-CoV-2 binding avidity. This construct can work as a decoy to block viral entry into host cells and is about 1,000-fold more potent than the free aptamer. In this R21 proposal, we aim to extend this technology to enable the incorporation of multiple types of probes against spike RBD and to validate the safety and effectiveness of DDNs in antiviral therapy in vitro and in vivo. We propose two specific aims: to (1) design, synthesize, validate, and further optimize the virus-capturing avidity against various SARS- CoV-2 variants of concern (VOCs); and (2) to determine the antiviral potency and cytotoxicity of the designed DDNs during SARS-CoV-2 infections in vitro in human lung epithelial cells and in vivo in human ACE2-knockin mice. Completion of this work will help us define the antiviral potency and safety of the DNA nanostructures that are designed to perfectly match epitope layouts on the viral surface to capture and wrap live viruses. The estimated cost of DDN treatment is approximately $10/dose (a price that likely decreases at large-scale synthesis), making it an affordable therapy. This DDN platform may further contribute to the rapid development of antiviral precision medicine against emerging SARS-CoV-2 VOCs, as well as other enveloped viruses such as influenza and HIV.", "keywords": [ "2019-nCoV", "ACE2", "Agar Gel Electrophoresis", "Animal Model", "Antigens", "Antiviral Therapy", "Area", "Atomic Force Microscopy", "Avidity", "Binding", "Biological Assay", "COVID-19", "Cell model", "Cells", "Characteristics", "Collection", "DNA", "Detection", "Development", "Dose", "Effectiveness", "Engineering", "Epithelial Cells", "Epitopes", "Etiology", "Exhibits", "Goals", "HIV", "Human", "In Vitro", "Infection", "Influenza", "Knock-in Mouse", "Knowledge", "Lung", "Mechanics", "Medicine", "Membrane Glycoproteins", "Membrane Proteins", "Molecular", "Molecular Genetics", "Nanostructures", "Nanotechnology", "Pattern", "Positioning Attribute", "Preventive", "Price", "Property", "Proteins", "Resistance", "Route", "SARS-CoV-2 infection", "SARS-CoV-2 inhibitor", "SARS-CoV-2 spike protein", "SARS-CoV-2 variant", "Safety", "Sensitivity and Specificity", "Series", "Shapes", "Structure", "Surface", "Technology", "Testing", "Therapeutic", "Toxic effect", "United States National Institutes of Health", "Validation", "Variant", "Viral", "Virion", "Virus", "Virus Diseases", "Work", "anti-viral efficacy", "antiviral drug development", "aptamer", "biomaterial compatibility", "cost", "cost estimate", "cytotoxic", "cytotoxicity", "design", "drug development", "flexibility", "future epidemic", "genetic technology", "in vivo", "innovation", "innovative technologies", "mimicry", "mouse model", "nano", "nanobodies", "nanoscale", "pandemic disease", "particle", "pathogen", "post SARS-CoV-2 infection", "precision medicine", "prevent", "programs", "prophylactic", "prototype", "receptor", "receptor binding", "screening", "transmission process", "variants of concern", "viral entry inhibitor" ], "approved": true } }, { "type": "Grant", "id": "11878", "attributes": { "award_id": "1R01AI173035-01A1", "title": "Blood DNA Methylation Biomarkers of Post AcuteSequelae of SARS CoV 2 Infection (PASC)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 10255, "first_name": "Joseph J.", "last_name": "Breen", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-07-05", "end_date": "2028-06-30", "award_amount": 812430, "principal_investigator": { "id": 27774, "first_name": "Reid Spencer", "last_name": "Alisch", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 27775, "first_name": "Adolfo Ariel", "last_name": "Jaitovich", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 2055, "ror": "", "name": "ALBANY MEDICAL COLLEGE", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "Project Summary: DNA 5'-C-phosphate-G-3' (CpG) methylation is a covalent epigenetic modification that regulates gene expression and is highly sensitive to age and environmental factors. Critically ill patients exhibit altered circulating blood DNA methylation profiles. We have recently reported a large scale methylome analysis of COVID-19 in association with clinical outcomes, which suggests an epigenetic regulation of genes controlling disease severity. Recent evidence indicates that many surviving COVID-19 patients develop long term dysfunctions and the NIH-NHLBI has recently launched an initiative to elucidate the nature of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC). It is currently unknown if the rapid methylome regulation evoked by acute illness persist after SARS-CoV-2 resolution. Such persistence could underpin long term sequela associated with this condition. Because DNA methylation is a relatively stable DNA chemical modification that could influence long-term gene expression profiles and given that we recently found that multiple regions developed during acute illness persist differentially methylated one year after hospital discharge, we hypothesize that COVID-19 infection leads to enduring DNA methylation abnormalities that remain after resolution of acute illness in association with the post-COVID-19 clinical profile. In this application, we plan to conduct whole genome DNA methylation and RNA sequencing of circulating leucocytes to establish sub phenotypes of PASC, predict future PASC development in the acute COVID-19, and determine which circulating leucocyte lineage contributes to that enduring methylome.", "keywords": [ "2019-nCoV", "Acute", "Acute respiratory failure", "Age Factors", "Blood", "Blood specimen", "COVID-19", "COVID-19 impact", "COVID-19 patient", "COVID-19 severity", "COVID-19 survivors", "Cell Separation", "Cells", "Cessation of life", "Chemicals", "Classification", "Clinical", "Cognitive", "Critical Illness", "DNA", "DNA Maintenance", "DNA Methylation", "DNA methylation profiling", "DNA sequencing", "Data", "Development", "Dimensions", "Dyspnea", "Environmental Risk Factor", "Epigenetic Process", "Exhibits", "Functional disorder", "Future", "Gene Expression", "Gene Expression Regulation", "Genomics", "Hospitalization", "Hospitals", "Immune", "Individual", "Inflammatory", "Integration Host Factors", "Leukocytes", "Long COVID", "Lymphoid", "Lymphoid Cell", "Magnetism", "Measures", "Methylation", "Mission", "Modification", "Molecular", "Muscle Weakness", "Myelogenous", "Myeloid Cells", "National Heart Lung and Blood Institute", "Nature", "Outcome", "Participant", "Patients", "Pattern", "Phenotype", "Population", "Positioning Attribute", "Post-Acute Sequelae of SARS-CoV-2 Infection", "Predisposition", "Process", "Public Health", "Publishing", "RNA", "RNA Sequences", "Recovery", "Regulation", "Reporting", "Research", "Resolution", "SARS-CoV-2 infection", "Sampling", "Sensitivity and Specificity", "Severity of illness", "Sleep Disorders", "Subgroup", "Testing", "Time", "Tissues", "Transcript", "United States National Institutes of Health", "Untranslated RNA", "acute infection", "chromatin modification", "clinical phenotype", "disorder control", "epigenetic regulation", "genome-wide", "histone modification", "individual response", "infection burden", "inorganic phosphate", "instrument", "long-term sequelae", "longitudinal analysis", "machine learning classification", "methylation biomarker", "methylome", "multiple omics", "novel", "post SARS-CoV-2 infection", "post-COVID-19", "transcriptome", "transcriptome sequencing", "whole genome" ], "approved": true } } ], "meta": { "pagination": { "page": 1392, "pages": 1424, "count": 14236 } } }